Basel Long COVID-19 Cohort Study and Digital Long COVID Substudy
NCT05781893, Completed, University Hospital, Basel, Switzerland
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Basel Long COVID-19 Cohort Study and Digital Long COVID Substudy | ClinicalTrials.gov |
| NCT number | NCT05781893 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 196 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University Hospital, Basel, Switzerland | ClinicalTrials.gov |
| Conditions | Post COVID-19 Condition (PCC) | ClinicalTrials.gov |
| Interventions | Digital intervention (DiLCoS), Data collection | ClinicalTrials.gov |
| First posted | 2023-03-23 | ClinicalTrials.gov |
| Last updated | 2026-07-29 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in World Health Organization Disability Assessment Schedule (WHODAS 2.0) (12- item version) | At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months) | The World Health Organization Disability Assessment Schedule (WHODAS 2.0) assesses and classifies disability due to health problems during the past 4 weeks. This study will utilize the 12- item version. Items are answered on a 5-point scale ranging from 0 = "none" to 4 = "extreme or cannot do". | ClinicalTrials.gov |
| Other | Change in Visual analogue scales (VAS) | At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months) | Patients will answer 4 questions on a VAS with a rating slider ranging from 0 to 10. The questions will inquire symptom intensity (10 = it can't be worse), functional impairment (10 = can't be worse), quality of life (10 = can't be better), and work capacity (10 = full work capacity). | ClinicalTrials.gov |
| Other | Change in EuroHIS Quality-of-Life-8 (QOL-8) | At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months) | This 8-item instrument assesses quality of life and perceived health during the past 4 weeks. Items are answered on a 5-point scale, with wording differing between questions (e.g., from "very dissatisfied" to "very satisfied"). | ClinicalTrials.gov |
| Other | Change in the Somatic Symptom Disorder Questionnaire (SSD-12) | At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months) | SSD-12 assesses psychological features of somatic disorders, e.g. catastrophizing thoughts and health anxiety. Items are answered on a 5-point scale ranging from 0 = "never" to 4 = "very often". | ClinicalTrials.gov |
| Other | Change in the Patient Health Questionnaire (PHQ-15) | At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months) | PHQ-15 assesses somatic symptom severity during the past 4 weeks. Patients are asked how impaired they felt by their symptoms, e.g. back pain. Items are answered on a 3-point scale ranging from 0 = "not bothered at all" to 2 = "bothered a lot". | ClinicalTrials.gov |
| Other | Change in the Patient Health Questionnaire Depression Scale (PHQ-8) | At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months) | PHQ-8 assesses the severity of depressive disorders. Patients are asked if in the past weeks, they were bothered by a problem. Items are answered on a 4-point scale ranging from 0 = "not at all" to 3 = "nearly every day". | ClinicalTrials.gov |
| Other | Change in the Generalized Anxiety Disorder Questionnaire (GAD-7) | At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months) | GAD-7 assesses if the patient was bothered by complaints related to anxiety during the past 2 weeks. Items are answered on a 4-point Likert scale ranging from 0 = "not at all" to 3 = "nearly every day". | ClinicalTrials.gov |
| Other | Change in the Resilience Scale (Resilience Scale (RS-11) | At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months) | The 11-item RS-11 asks about general resilience towards life events. Items are answered on a 7-point scale ranging from 1 = "strongly agree" to 7 = "strongly disagree". | ClinicalTrials.gov |
| Other | Change in the Insomnia Severity Index (ISI) | At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months) | Insomnia, e.g. difficulty falling asleep, is assessed by the ISI. Items are answered on a 5-point scale with regards to severity during the past 2 weeks, with wording differing between questions (e.g., from 0 = "very dissatisfied" to 4 = "very satisfied"). | ClinicalTrials.gov |
| Other | Change in the Chalder Fatigue Scale | At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months) | Fatigue is assessed by the 11-item Chalder Fatigue Scale. Items are answered on a 4-point scale ranging from 0 = "Better than usual" to 3 = "much worse than usual". | ClinicalTrials.gov |
| Other | Change in the Perceived Stress Scale (PSS) | At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months) | The PSS investigates the experience of psychological stress in the past 4 weeks. It consists of 10 items. Items are answered on a 5-point scale ranging from 1 = "never" to 5 = "very often". | ClinicalTrials.gov |
| Other | Change in JAMAR® grip strength test on the dominant hand | At Baseline and T3 (BL + 12 months) | Grip strength will be assessed using the JAMAR®, a hydraulic grip strength measuring device (American Society for Surgery of the Hand, 1983). The test is repeated thrice for the dominant hand. The best value (in kg) is taken. | ClinicalTrials.gov |
| Other | Change in 6-minute walking test | At Baseline and T3 (BL + 12 months) | 6-minute walking test is to assess functional exercise capacity by measuring the distance (in meters total) that a patient can walk in 6 minutes. Well-being before and after the test is assessed on a 5-point Likert-scale ranging from 1 = "very bad" to 5 = "very good". After the test, perceived exertion of breathing and legs is assessed with the Borg Category-Ratio (CR) 10 Scale ranging from 0 = "no exertion" to 10 = "maximal exertion" | ClinicalTrials.gov |
| Other | Change in one minute sit-to-stand test (STS-60) | At Baseline and T3 (BL + 12 months) | STS-60 is a measure for muscular endurance. It assesses the number of sit-to-stand cycles that can be achieved within one minute. | ClinicalTrials.gov |
| Other | Change in neurocognitive status of patients assessed by CNS Vital Signs (CNSVS) test | At Baseline and T3 (BL + 12 months); approximately 40-50 minutes per test battery | CNSVS is a computerized neurocognitive test battery that was developed as a routine clinical screening instrument. It consists of seven scientifically valid and reliable neuropsychological tests that normally require an interviewer. The tests are: verbal and visual memory, finger tapping, symbol digit coding, the Stroop Test, a test of shifting attention, and the continuous performance test. The Neurocognition Index reflects the overall or global neurocognitive functioning of the test taker. It is an average or the standard scores for five of the domains (composite memory, psychomotor speed, reaction time, complex attention and cognitive flexibility) that reflect the patient's performance on each assessment. CNS Vital Signs standardized have a mean of 100 and a standard deviation is 15. Higher scores are always better. | ClinicalTrials.gov |
| Other | (Only BALCoS w/ DiLCoS) Progress and patients' engagement assessed by weekly feedback questions | After BL and before T1; at day 6 in weeks 1-11 | Patients enrolled in DiLCoS are presented with questions for qualitative feedback at the end of each weekly module within the digital intervention | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 40645616 | DERIVED | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Continuous Performance Test | Other outcome | ConductCognition |
| Stroop Color-Word Test | Other outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)